Head to Head Survey: Aeglea Bio Therapeutics (AGLE) and The Competition
Aeglea Bio Therapeutics (NASDAQ: AGLE) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Aeglea Bio Therapeutics to related companies based on the strength of its valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
This is a breakdown of recent recommendations and price targets for Aeglea Bio Therapeutics and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aeglea Bio Therapeutics||0||0||0||0||N/A|
|Aeglea Bio Therapeutics Competitors||815||3185||11552||230||2.71|
Institutional and Insider Ownership
46.9% of Aeglea Bio Therapeutics shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 27.0% of Aeglea Bio Therapeutics shares are held by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Aeglea Bio Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aeglea Bio Therapeutics||$4.63 million||-$21.69 million||-2.58|
|Aeglea Bio Therapeutics Competitors||$284.30 million||$34.29 million||126.98|
Aeglea Bio Therapeutics’ rivals have higher revenue and earnings than Aeglea Bio Therapeutics. Aeglea Bio Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Aeglea Bio Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aeglea Bio Therapeutics||-527.99%||-44.05%||-41.00%|
|Aeglea Bio Therapeutics Competitors||-5,335.75%||-434.35%||-39.86%|
Aeglea Bio Therapeutics rivals beat Aeglea Bio Therapeutics on 5 of the 8 factors compared.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.
Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.